Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 18/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736290 | 0.88 | ESR1 (0.51) | CETPESR1ESR2KCNH2CEPT1 | |
| SCHEMBL1734999 | 0.86 | ESR1 (0.49) | CETPESR1ESR2KCNH2CEPT1 | |
| SCHEMBL1735124 | 0.85 | ESR1 (0.48) | CETPESR1ESR2KCNH2 | |
| SCHEMBL1735106 | 0.84 | CETP (0.54) | CETPESR1ESR2KCNH2CEPT1 | |
| SCHEMBL1735063 | 0.84 | ESR1 (0.54) | CETPESR1ESR2KCNH2CEPT1 | |
| SCHEMBL1734615 | 0.84 | CETP (0.51) | CETPESR1ESR2KCNH2 | |
| SCHEMBL1734027 | 0.81 | ESR1 (0.51) | CETPESR1ESR2KCNH2CEPT1 | |
| SCHEMBL1735013 | 0.81 | ESR1 (0.51) | CETPESR1ESR2KCNH2CEPT1 | |
| SCHEMBL15088548 | 0.81 | CETP (0.58) | CETPESR1ESR2KCNH2 | |
| SCHEMBL2836341 | 0.81 | CETP (0.58) | CETPESR1ESR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| EP-1954287-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | CETP 1/4885ESR1 3810/4885ESR2 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.